Composition of certain financial statement captions |
| | | | | | | | | (In thousands) | June 30, 2015 | | December 31, 2014 | Accounts receivable, net | | | | Accounts receivable | $ | 29,045 |
| | $ | 21,875 |
| Less: allowance for doubtful accounts | (2,065 | ) | | (1,906 | ) | | $ | 26,980 |
| | $ | 19,969 |
| Inventories, net | | | | Finished products | $ | 13,830 |
| | $ | 12,116 |
| Work in-process | 1,619 |
| | 1,011 |
| Raw materials | 5,782 |
| | 4,116 |
| Less: inventory reserve | (712 | ) | | (639 | ) | | $ | 20,519 |
| | $ | 16,604 |
| Prepaid expenses and other current assets | | | | Prepaid supplies | $ | 1,441 |
| | $ | 1,123 |
| Prepaid insurance | 613 |
| | 968 |
| Other receivables | 1,107 |
| | 669 |
| Taxes recoverable | 3,074 |
| | 2,417 |
| Other | 3,388 |
| | 4,212 |
| | $ | 9,623 |
| | $ | 9,389 |
| Intangible assets, net: | | | | Technologies | $ | 52,287 |
| | $ | 52,508 |
| Customer relationships | 55,750 |
| | 22,108 |
| Product registrations | 8,088 |
| | 8,763 |
| Trade names | 3,411 |
| | 3,483 |
| Covenants not to compete | 8,620 |
| | 8,639 |
| Other | 4,889 |
| | 1,079 |
| Less: accumulated amortization | (38,798 | ) | | (33,931 | ) | | $ | 94,247 |
| | $ | 62,649 |
| Accrued expenses: | | | | Taxes payable | $ | 2,592 |
| | $ | 77 |
| Deferred revenue | 75,159 |
| | 4,185 |
| Clinical trials | 8,534 |
| | 8,643 |
| Professional fees | 1,724 |
| | 1,860 |
| Employee benefits | 5,456 |
| | 4,127 |
| Contingent consideration | 41,146 |
| | 27,352 |
| Other | 15,232 |
| | 14,668 |
| | $ | 149,843 |
| | $ | 60,912 |
| | | | |
| | | | | | | | | (In thousands) | June 30, 2015 | | December 31, 2014 | Other long-term liabilities: | | | | Contingent consideration – OPKO Renal | $ | 19,183 |
| | $ | 36,529 |
| Contingent consideration – OPKO Health Europe | 225 |
| | 254 |
| Contingent consideration – OPKO Diagnostics | 13,342 |
| | 6,992 |
| Contingent consideration – CURNA | 433 |
| | 440 |
| Mortgages and other debts payable | 2,148 |
| | 2,434 |
| Deferred tax liabilities | 172,458 |
| | 167,153 |
| Deferred revenue | 197,279 |
| | 2,526 |
| Other | 3,753 |
| | 1,030 |
| | $ | 408,821 |
| | $ | 217,358 |
|
|
Schedule of goodwill |
The following table reflects the changes in Goodwill during the six months ended June 30, 2015. | | | | | | | | | | | | | | | | | | 2015 | (In thousands) | Balance at January 1st | | Acquisitions | | Foreign exchange | | Balance at June 30th | Pharmaceuticals | | | | | | | | CURNA | $ | 4,827 |
| | $ | — |
| | $ | — |
| | $ | 4,827 |
| OPKO Mexico | 100 |
| | — |
| | (5 | ) | | 95 |
| OPKO Chile | 5,283 |
| | — |
| | (243 | ) | | 5,040 |
| OPKO Health Europe | 8,013 |
| | — |
| | (699 | ) | | 7,314 |
| FineTech | 11,698 |
| | — |
| | — |
| | 11,698 |
| SciVac | 1,553 |
| | — |
| | 49 |
| | 1,602 |
| OPKO Renal | 2,069 |
| | — |
| | — |
| | 2,069 |
| OPKO Biologics | 139,784 |
| | — |
| | — |
| | 139,784 |
| EirGen Pharma Ltd | — |
| | 66,823 |
| | (610 | ) | | 66,213 |
| Diagnostics | | | | | | | | OPKO Diagnostics
| 17,977 |
| | — |
| | — |
| | 17,977 |
| OPKO Lab | 32,988 |
| | — |
| | — |
| | 32,988 |
| | $ | 224,292 |
| | $ | 66,823 |
| | $ | (1,508 | ) | | $ | 289,607 |
|
|